Since metastatic disease mostly arises from M3 tumors, our findings of M3 tumors being resistant to MEK inhibition is in line with the failure of MEK inhibitors in clinical studies [21,22]. This evidence concerns the gene MAP2K7 and metastatic neoplasm.